Astellas Pharma Inc. (ALPMF)
10.12
1.25 (14.09%)
Apr 25, 2025, 10:41 AM - Market open
14.09% (1D)
| Bid | 9.1 |
| Market Cap | 18.12B |
| Revenue (ttm) | 1,701.8B |
| Net Income (ttm) | 17.38B |
| EPS (ttm) | 0.2 |
| PE Ratio (ttm) | 50.6 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 10.27 |
| Volume | 200 |
| Avg. Volume (20D) | 1,314 |
| Open | 10.12 |
| Previous Close | 8.87 |
| Day's Range | 10.12 - 10.12 |
| 52-Week Range | 8.40 - 12.74 |
| Beta | 0.17 |
About ALPMF
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a ...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Apr 26, 2010
Employees 14,754
Stock Exchange PNK
Ticker Symbol ALPMF
Website https://www.astellas.com
